Nissen, M J; Ciurea, A; Bernhard, J; Tamborrini, G; Mueller, R; Weiss, B; Toniolo, M; Exer, P; Finckh, A (2016). The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis and Rheumatology, 68(9):2141-2150.
Mueller, R B; Schiff, M; Kaegi, T; Finckh, A; Haile, Sarah R; Schulze-Koops, H; von Kempis, J (2015). The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clinical Rheumatology, 34(1):51-59.
Kyburz, D; Gabay, C; Michel, B A; Finckh, A (2011). The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology, 50(6):1106-1110.
Finckh, A; Ciurea, A; Brulhart, L; Möller, B; Walker, U A; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2010). Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Annals of the Rheumatic Diseases, 69(2):387-393.
Finckh, A; Dudler, J; Wermelinger, F; Ciurea, A; Kyburz, D; Gabay, C; Bas, S (2010). Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint, Bone, Spine, 77(4):313-318.
Dudler, J; Finckh, A; Kyburz, D; Langenegger, T; Möller, B; Schmiedel, U; Walker, U A (2010). Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Medical Weekly, (140):w13073.
Finckh, A; Dehler, S; Gabay, C (2009). The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Annals of the Rheumatic Diseases, 68(1):33-39.
Du Pan, S M; Dehler, S; Ciurea, A; Ziswiler, H R; Gabay, C; Finckh, A (2009). Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis and Rheumatism, 61(5):560-568.
Finckh, A; Ciurea, A; Brulhart, L; Kyburz, D; Möller, B; Dehler, S; Revaz, S; Dudler, J; Gabay, C (2007). B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis and Rheumatism, 56(5):1417-1723.
Finckh, A; Dehler, S; Costenbader, K H; Gabay, C (2007). Cigarette smoking and radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases, 66(8):1066-1071.